This study further explored the potential application of Ex-DARP-FGF21 and Ex-DARP in treating T2DM by subcutaneously administering these compounds to DIO mice at 30 nmol/kg once every three days for 30 consecutive days. The gene discussed is FGF21; the disease is type 2 diabetes mellitus.